Edition:
United Kingdom

Cytokinetics Inc announces negative results from VITALITY-ALS


Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Cytokinetics Inc :Cytokinetics announces negative results from VITALITY-ALS.Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints​.No new safety or tolerability findings related to Tirasemtiv were identified in VITALITY-ALS​.Believe that limitations of Tirasemtiv may be addressed with co's next-generation fast skeletal muscle activator, CK-2127107​.Have decided to suspend development of Tirasemtiv​.Limitations of Tirasemtiv may be addressed with co's "next-generation fast" skeletal muscle activator, CK-2127107​.Believe CK-2127107 will be better tolerated, potentially more effective than Tirasemtiv for ALS & look forward to phase 2 results in 2018​. 

Related Company News

Company Quote

7.61
 --
12 Oct 2018